Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.850
+0.050 (2.78%)
At close: Dec 20, 2024, 4:00 PM
1.890
+0.040 (2.16%)
After-hours: Dec 20, 2024, 4:27 PM EST
Acumen Pharmaceuticals Employees
As of December 31, 2023, Acumen Pharmaceuticals had 52 total employees, including 51 full-time and 1 part-time employees. The number of employees increased by 12 or 30.00% compared to the previous year.
Employees
52
Change (1Y)
12
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,570,615
Market Cap
111.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 52 | 12 | 30.00% |
Dec 31, 2022 | 40 | 23 | 135.29% |
Dec 31, 2021 | 17 | 10 | 142.86% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
MultiPlan | 2,800 |
Editas Medicine | 265 |
Tenaya Therapeutics | 140 |
X4 Pharmaceuticals | 93 |
Leap Therapeutics | 54 |
Cassava Sciences | 29 |
Protara Therapeutics | 27 |
MediciNova | 13 |
ABOS News
- 25 days ago - Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewsWire
- 5 weeks ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference - GlobeNewsWire
- 2 months ago - Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 2 months ago - Lucy Therapeutics Appoints Kim Drapkin as Board Chair - Business Wire
- 2 months ago - Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - GlobeNewsWire